Skip to content
Invirase(saquinavir)
Fortovase, Invirase (saquinavir) is a small molecule pharmaceutical. Saquinavir was first approved as Invirase on 1995-12-06. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Saquinavir
Tradename
Company
Number
Date
Products
FORTOVASERocheN-020828 DISCN1997-11-07
1 products, RLD
Hide discontinued
Saquinavir mesylate
Tradename
Company
Number
Date
Products
INVIRASERocheN-020628 DISCN1995-12-06
1 products, RLD
INVIRASERocheN-021785 DISCN2004-12-17
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
inviraseNew Drug Application2020-12-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE01: Saquinavir
HCPCS
Code
Description
S0140
Saquinavir, 200 mg
Clinical
Clinical Trials
72 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201629137666
Cardiovascular diseasesD002318EFO_0000319I98———1—1
Hiv-associated lipodystrophy syndromeD039682EFO_1001348———1—1
Healthy volunteers/patients————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Directly observed therapyD023801——1——1
Aids-associated nephropathyD016263EFO_0007313——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD0000810291————1
PregnancyD011247EFO_0002950Z33.11————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSAQUINAVIR
INNsaquinavir
Description
Saquinavir is an aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease. It has a role as a HIV protease inhibitor and an antiviral drug. It is a member of quinolines and a L-asparagine derivative.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
Identifiers
PDB—
CAS-ID127779-20-8
RxCUI83395
ChEMBL IDCHEMBL114
ChEBI ID63621
PubChem CID441243
DrugBankDB01232
UNII IDL3JE09KZ2F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,340 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
356 adverse events reported
View more details